With its largest-ever acquisition, Angelini gains 24-year-old Catalyst, which was listed on the Nasdaq in 2006. Catalyst ...

With President Donald Trump recently signing an executive order to accelerate research and ease the restrictions on ...

Alnylam with an untitled letter over the consumer website for Amvuttra, accusing the biotech | The FDA has hit Alnylam with ...

After a surprise rejection at the beginning of 2026, the FDA has agreed to reconsider a T-cell therapy based on the same ...

Insulet has always been a strong leader in the medtech industry when it comes to its marketing game—and the diabetes device maker isn’t looking to rest on its laurels.  | Insulet has always been a ...

Since it was established nearly a year ago by the FDA, the Commissioner’s National Priority Voucher (CNPV) program has been ...

With commitments to invest more than $50 billion in building up its U.S. manufacturing presence, Eli Lilly has earmarked an ...

In France, Wegovy is prescribed as a second-line treatment for obesity, not for people with a lower body mass index (BMI) or ...

Following a series of “most favored nation” (MFN) pricing deals with 17 large pharma companies, the Trump administration ...

In the latest update to COVID and vaccine-related discourse bubbling up at the FDA, agency officials have recently blocked ...

In a bid to better deploy its boots-on-the-ground resources, the FDA is pulling back the curtain on a new pilot program, under which the regulator is leveraging “one-day inspectional assessments” to ...

Sanofi is supercharging its artificial intelligence capabilities. | Sanofi is supercharging its artificial intelligence ...